Zhuhai Gene-Biocon Biological Technology

Zhuhai Gene-Biocon Biological Technology is a Chinese biopharmaceutical company specializing in the development and production of recombinant protein and peptide therapeutics. The company is best known for its flagship product, recombinant human pro-urokinase (rhpro-UK), which is marketed under the brand name Pujinli for the treatment of acute myocardial infarction. Gene-Biocon utilizes proprietary high-yield protein expression and purification platforms to maintain a pipeline focused on cardiovascular, metabolic, and neurological indications. Their manufacturing facilities in Zhuhai are GMP-certified, supporting large-scale production of biologics for both internal programs and potential partners. The company is also advancing several peptide-based candidates, including recombinant versions of GLP-1 receptor agonists for the management of type 2 diabetes.